Journal Watch · Journal of Clinical Oncology · 2026

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.

Tahara M, Kiyota N, Kodaira T et al.Journal of Clinical Oncology3 min readPharma relevance 75/100

DOI: 10.1200/jco-25-01708PMID: 42361282Study type: randomised / controlled clinical trial

TL;DR

These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.

Key findings

  • No late adverse event showed more than a 10% difference between the two arms.
  • In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN.
  • These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.

Numbers at a glance (from the abstract)

58.7%71.2%95%10%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm.

Full abstract (original)

Background: The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m<sup>2</sup> once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m<sup>2</sup> once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin.

What they did: A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm.

Results & conclusions: No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.

Abstract © the authors / Journal of Clinical Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1200/jco-25-01708 · PubMed 42361282.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Clinical Oncology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Journal of Clinical Oncology study find?

These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.

What type of study is this?

It is a randomised / controlled clinical trial, published in Journal of Clinical Oncology in 2026. A total of 261 patients were enrolled.

Where can I read the original paper?

The original is at the publisher via DOI 10.1200/jco-25-01708. PubMed ID: 42361282. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Tahara M, Kiyota N, Kodaira T et al.. Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.. Journal of Clinical Oncology (2026). DOI: 10.1200/jco-25-01708.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/long-term-follow-up-of-jcog1008-a-randomized-phase-ii-iii-trial-of-chemo-501708/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides